* Highlights positive results from pivotal phase 3 FULFIL
study of the closed triple announced by GlaxoSmithKline and
Innoviva at ERS international congress

The post BRIEF-Theravance Biopharma says positive results received from late stage FULFIL study appeared first on NASDAQ.